Adlercreutz, H (2002) Phyto-oestrogens and cancer. Lancet Oncol 3, 364–373.
Akaza, H, Miyanaga, N, Takashima, N, Naito, S, Hirao, Y, Tsukamoto, T & Mori, M (2002) Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 32, 296–300.
Akaza, H, Miyanaga, N, Takashima, N, et al. (2004) Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 34, 86–89.
Arnold, JT, Le, H, McFann, KK & Blackman, MR (2005) Comparative effects of DHEA versus testosterone, dihydrotestosterone and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol 288, E573–E584.
Beck, V, Unterrieder, E, Krenn, L, Kubelka, W & Jungbauer, A (2003) Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 84, 259–268.
Bloedon, LT, Jeffcoat, AR, Lopaczynski, W, Schell, MJ, Black, TM, Dix, KJ, Thomas, BF, Albright, C, Busby, MG, Crowell, JA & Zeisel, SH (2002) Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr 76, 1126–1137.
Dagnelie, PC, Schuurman, AG, Goldbohm, RA & Van den Brandt, PA (2004) Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 93, 1139–1150.
Di, Virgilio AL, Iwami, K, Watjen, W, Kahl, R & Degen, GH (2004) Genotoxicity of the isoflavones genistein, daidzein and equol in V79 cells. Toxicol Lett 151, 151–162.
Gomez, SL, Le, GM, Clarke, CA, Glaser, SL, France, AM & West, DW (2003) Cancer incidence patterns in Koreans in the US and in Kangwha, South Korea. Cancer Causes Control 14, 167–174.
Hedlund, TE, Johannes, WU & Miller, GJ (2003) Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 54, 68–78.
Hedlund, TE, Maroni, PD, Ferucci, PG, Dayton, R, Barnes, S, Jones, K, Moore, R, Ogden, LG, Wahala, K, Sackett, HM & Gray, KJ (2005) Long-term dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in caucasian men. J Nutr 135, 1400–1406.
Heinonen, S, Wahala, K & Adlercreutz, H (1999) Identification of isoflavone metabolites dihydrodaidzein, dihydrogenistein, 6′-OH-O-DMA, and cis-4-OH-equol in human urine by gas chromatography-mass spectroscopy using authentic reference compounds. Anal Biochem 274, 211–219.
Hsing, AW, Tsao, L & Devesa, SS (2000) International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85, 60–67.
Igawa, T, Lin, FF, Lee, MS, Karan, D, Batra, SK & Lin, MF (2002) Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50, 222–235.
Jemal, A, Thomas, A, Murray, T & Thun, M (2002) Cancer statistics, 2002. CA Cancer J Clin 52, 23–47.
Klein, KA, Reiter, RE, Redula, J, et al. (1997) Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3, 402–408.
Kuiper, GG, Carlsson, B, Grandien, K, Enmark, E, Haggblad, J, Nilsson, S & Gustafsson, JA (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138, 863–870.
Kuiper, GG, Lemmen, JG, Carlsson, B, Corton, JC, Safe, SH, van der Saag, PT, van der, BB & Gustafsson, JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139, 4252–4263.
Kulling, SE, Honig, DM & Metzler, M (2001) Oxidative metabolism of the soy isoflavones daidzein and genistein in humans in vitro and in vivo. J Agric Food Chem 49, 3024–3033.
Kulling, SE & Metzler, M (1997) Induction of micronuclei, DNA strand breaks and HPRT mutations in cultured Chinese hamster V79 cells by the phytoestrogen coumoestrol. Food Chem Toxicol 35, 605–613.
Lee, C, Sutkowski, DM, Sensibar, JA, Zelner, D, Kim, I, Amsel, I, Shaw, N, Prins, GS & Kozlowski, JM (1995) Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136, 796–803.
Liggins, J, Bluck, LJ, Runswick, S, Atkinson, C, Coward, WA & Bingham, SA (2000) Daidzein and genistein contents of vegetables. Br J Nutr 84, 717–725.
Maggiolini, M, Vivacqua, A, Carpino, A, Bonofiglio, D, Fasanella, G, Salerno, M, Picard, D & Ando, S (2002) The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. Mol Pharmacol 62, 1027–1035.
Miltyk, W, Craciunescu, CN, Fischer, L, Jeffcoat, RA, Koch, MA, Lopaczynski, W, Mahoney, C, Jeffcoat, RA, Crowell, J, Paglieri, J & Zeisel, SH (2003) Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77, 875–882.
Mitchell, JH, Duthie, SJ & Collins, AR (2000) Effects of phytoestrogens on growth and DNA integrity in human prostate tumor cell lines: PC-3 and LNCaP. Nutr Cancer 38, 223–228.
Morton, MS, Arisaka, O, Miyake, N, Morgan, LD & Evans, BA (2002) Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 132, 3168–3171.
Morton, MS, Chan, PS, Cheng, C, Blacklock, N, Matos-Ferreira, A, Branches-Monteiro, L, Correia, R, Lloyd, S & Griffiths, K (1997) Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom. Prostate 32, 122–128.
Murata, M, Midorikawa, K, Koh, M, Umezawa, K & Kawanishi, S (2004) Genistein and daidzein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs. Biochemistry 43, 2569–2577.
Onozawa, M, Fukuda, K, Ohtani, M, Akaza, H, Sugimura, T & Wakabayashi, K (1998) Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Jpn J Clin Oncol 28, 360–363.
Ozasa, K, Nakao, M, Watanabe, Y, et al. (2004) Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 95, 65–71.
Pool-Zobel, BL, Adlercreutz, H, Glei, M, Liegibel, UM, Sittlingon, J, Rowland, I, Wahala, K & Rechkemmer, G (2000) Isoflavonoids and lignans have different potentials to modulate oxidative genetic damage in human colon cells. Carcinogenesis 21, 1247–1252.
Quinn, M & Babb, P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90, 162–173.
Record, IR, Jannes, M, Dreosti, IE & King, RA (1995) Induction of micronucleus formation in mouse splenocytes by the soy isoflavone genistein in vitro but not in vivo. Food Chem Toxicol 33, 919–922.
Ren, MQ, Kuhn, G, Wegner, J & Chen, J (2001) Isoflavones, substances with multi-biological and clinical properties. Eur J Nutr 40, 135–146.
Sack, JS, Kish, KF, Wang, C, et al. (2001) Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98, 4904–4909.
Schaeferhenrich, A, Beyer-Sehlmeyer, G, Festag, G, et al. (2003) Human adenoma cells are highly susceptible to the genotoxic action of 4-hydroxy-2-nonenal. Mutat Res 526, 19–32.
Schmitt, E, Metzler, M, Jonas, R, Dekant, W & Stopper, H (2003) Genotoxic activity of four metabolites of the soy isoflavone daidzein. Mutat Res 542, 43–48.
Schuurmans, AL, Bolt, J, Veldscholte, J & Mulder, E (1991) Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J Steroid Biochem Mol Biol 40, 193–197.
Shimizu, H, Ross, RK, Bernstein, L, Yatani, R, Henderson, BE & Mack, TM (1991) Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 63, 963–966.
Suzuki, H, Ueda, T, Ichikawa, T & Ito, H (2003) Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10, 209–216.
Taplin, ME, Bubley, GJ, Ko, YJ, Small, EJ, Upton, M, Rajeshkumar, B & Balk, SP (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59, 2511–2515.
Valsta, LM, Kilkkinen, A, Mazur, W, Nurmi, T, Lampi, AM, Ovaskainen, ML, Korhonen, T, Adlercreutz, H & Pietinen, P (2003) Phyto-oestrogen database of foods and average intake in Finland. Br J Nutr 89, Suppl. 1, S31–S38.
van Erp-Baart, MA, Brants, HA, Kiely, M, Mulligan, A, Turrini, A, Sermoneta, C, Kilkkinen, A & Valsta, LM (2003) Isoflavone intake in four different European countries: the VENUS approach. Br J Nutr 89, Suppl. 1, S25–S30.
Watanabe, S, Yamaguchi, M, Sobue, T, Takahashi, T, Miura, T, Arai, Y, Mazur, W, Wahala, K & Adlercreutz, H (1998) Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr 128, 1710–1715.
Wiseman, H, Casey, K, Bowey, EA, Duffy, R, Davies, M, Rowland, IR, Lloyd, AS, Murray, A, Thompson, R & Clarke, DB (2004) Influence of 10 wk of soy consumption on plasma concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy adults. Am J Clin Nutr 80, 692–699.